H.C. Wainwright reiterates Buy rating on Travere Therapeutics stock

Investing.com - H.C. Wainwright has reiterated its Buy rating and $47.00 price target on Travere Therapeutics (NASDAQ:TVTX). The stock, currently trading at $24.85, has shown remarkable momentum with an 8% gain in the past week and a 42.65% return year-to-date. According to InvestingPro, analysts maintain a Strong Buy consensus with targets ranging from $25 to $47.

The research firm’s decision follows Travere’s September 18 announcement that the Kidney Disease: Improving Global Outcomes (KDIGO) organization published its final 2025 Clinical Practice Guidelines for IgA Nephropathy (IgAN).

The updated KDIGO guidelines position Travere’s FILSPARI (sparsentan) as a foundational first-line therapy for IgAN for the first time, representing a significant development for the treatment.

H.C. Wainwright views these final KDIGO guidelines as a strong endorsement of FILSPARI’s clinical profile and believes they will positively impact physician adoption of the therapy.

The firm also noted that by positioning sparsentan as a foundational first-line option for at-risk IgAN patients, KDIGO provides a framework that could help guide future clinical practice and support expanded patient access globally.

In other recent news, Travere Therapeutics announced that the FDA will no longer require an advisory committee meeting for the supplemental New Drug Application (sNDA) of its drug FILSPARI, aimed at treating focal segmental glomerulosclerosis (FSGS). The Prescription Drug User Fee Act (PDUFA) date for this application remains set for January 13, 2026. This development has been positively received, with H.C. Wainwright reiterating its Buy rating and maintaining a $47.00 price target, citing the adapted Risk Evaluation and Mitigation Strategy (REMS) as a competitive advantage.

Jefferies also maintained its Buy rating with a $35.00 price target, viewing the cancellation of the advisory committee meeting as a significant positive step, indicating FDA support for using urine protein-to-creatinine ratio (UPCR) as the primary endpoint for full approval in FSGS. Cantor Fitzgerald reiterated an Overweight rating on Travere shares following the announcement. These recent developments reflect a supportive stance from the FDA and continued confidence from analysts in Travere’s prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.